ࡱ> %'"#$ bjbj &2B6 6 yyD1111hzIL("""yyyyyyyZ|~ryD&!"D&D&yyyz$L1L1L1D&yRyL1D&yL1L1s"uvP,1>'~t6y,z<hzuVn(nluvnuvh"#L1g$%A"""yy/"""hzD&D&D&D&n"""""""""6 ?:  This document represents voluntary guidance for the pharmaceutical excipient industry and the contents should not be interpreted as regulatory requirements. Alternative approaches to those described in this guide may be implemented. FOREWORD IPEC is an international industry association formed in 1991 by manufacturers and end-users of excipients. It is an association comprising four regional pharmaceutical excipient industry associations covering the United States, Europe, China and Japan (which are known respectively as IPEC-Americas, IPEC Europe, IPEC-China and JPEC). IPECs objective is to contribute to the development and harmonization of international excipient standards, the introduction of useful new excipients to the marketplace and the development of best practice and guidance concerning excipients. IPEC has three major stakeholder groups; Excipient manufacturers and distributors, who are considered suppliers in this document, Pharmaceutical manufacturers, who are called users, and Regulatory authorities who regulate medicines.  EMBED Visio.Drawing.11  This document offers best practice and guidance in the establishment of a quality agreement between a buyer and a supplier of an excipient. The excipient supplier may be a manufacturer or a distributor (or both). The Guide highlights the factors to consider when planning and executing a such agreement between the parties. ACKNOWLEDGEMENTS This guideline is the result of the hard work and substantial resources, of IPEC member companies. IPEC greatly appreciates the many hours the following individuals devoted to develop this guide and the generous support of their employers for providing the necessary time and resources. IPEC-AMERICAS Alexa Smith, Colorcon Priscilla Zawislak, Hercules Incorporated Craig Scott, JRS Pharma LP Laura Horne, Mutchler, Inc. David B. Klug, sanofi-aventis Maria Guazzaroni Jacobs, Pfizer Londa Ritchey, Wyeth Chris Armstrong, Evonik Judy Emmert, Abbott Ann Van Meter, Dow Cindy Libonati, Purdue Pharma L.P. IPEC EUROPE Johanna Eisele, Evonik Rhm GmbH Karen M. Hudson,, Lilly UK Iain Moore, Ph.D., Croda Europe Ltd, INTRODUCTION In the current regulatory environment surrounding excipients, pharmaceutical manufacturers are under increasing pressure to develop better knowledge of their excipient supply chain. As part of solidifying supplier relationships, quality agreements have been introduced because they are considered to be beneficial in a supply relationship and are required in some jurisdictions for manufacturing under contract. They enable excipient users and suppliers to create a quality partnership between the two companies. Quality agreements are legally binding agreements that are mutually negotiated between users and suppliers of excipients. They are intended to be an agreement between quality departments. The purpose of the quality agreement is to define who is responsible for quality activities and how quality issues will be resolved that will allow excipient suppliers to provide safe products that are suitable for the users intended application. By clearly delineating GMP (good manufacturing practice) responsibilities, costly product quality issues resulting from miscommunication can be reduced or eliminated. Due to the increasing desire to have quality agreements in place with key suppliers, there has been a trend to use templates to get a large number of agreements in place quickly. Many companies, both users and suppliers, have developed their own templates to address quality agreements. Unfortunately, these individual templates have often been designed to cover multiple types of products (excipients, active pharmaceutical ingredients and/or packaging) and been presented in an inflexible manner. The result of this has been extensive negotiations between companies, significant time and resources spent, and fewer agreements completed. IPEC is committed to improving communications between excipient users and suppliers. As part of that on-going effort, IPEC has developed the IPEC Quality Agreement Template. The IPEC Quality Agreement Template is designed to provide excipient users and suppliers a common starting point to create quality agreements that address fundamental quality issues specific to the manufacture and use of excipients. By utilizing the IPEC Quality Agreement Template, users and suppliers will be able to reduce the time and effort needed to complete successful quality agreements. Having appropriate quality agreements in place can significantly improve communications, limit product quality issues that result from misunderstandings, and improve supply chain relationships. SCOPE AND PURPOSE The IPEC Quality Agreement Template is designed to be a flexible model for crafting quality agreements where an agreement is desired. It is intended to define the appropriate topics that should be addressed in a quality agreement related to excipients. The template is designed to be global in scope thus being suitable for use in many regions. There is both a manufacturer template and a distributor template. The information below is provided to assist in determining which template is appropriate for the individual situation. Manufacturer Template: Designed for use between the original manufacturer and either the end user or a distributor. The original manufacturer is the company manufacturing a material to the stage at which it is designated as a pharmaceutical starting material. Distributor Template: Designed for use between the distributor and the end user. Distributors are those parties handling the excipient after the point at which the excipient is transferred outside the control of the original manufacturers material management system. Distributors include those parties involved in trade and distribution, reprocessors, repackagers, transport and warehousing companies, forwarding agents, brokers, traders and suppliers other than the original manufacturer. A quality agreement is intended to be a formalized, joint agreement on quality responsibilities and activities defining both the users and suppliers respective obligations as they relate to quality. They are intended to address quality commitments between the parties and are based on the quality procedures in place. However, quality agreements cannot take the place of an audit. Quality agreements are not designed to replace commercial supply agreements but rather complement them. Other agreements may contain references to quality responsibilities and activities. During periodic reviews of these other agreements, excipient users and suppliers may wish to consider replacing specific quality information in the agreement with reference to a quality agreement. FORMAT OF THE EXCIPIENT QUALITY AGREEMENT DOCUMENTS The IPEC Quality Agreement Template format is a combination of a legal-style format and a tabular format. The Introduction/Purpose section of the template is presented in a legal-style format and the Quality Responsibilities section is presented in a tabular format. The legal style format addresses the terms and conditions and scope of the agreement. The tabular format allows for quick and easy identification of quality responsibilities which are the central point of the agreement. The template addresses the main quality points and responsibilities that should be included in a quality agreement appropriate for excipients; however, it does not list every element of the quality system used. It is not necessary to reiterate agreement on every point of the quality system when general agreement on the applicable quality criteria has been stated. However, included in the template are quality responsibilities that may require action by one or both parties. The format is intended to be flexible with the template offering the elements needed for most excipient quality agreements. Modifying the template should be done with care and only as necessary to avoid lengthy negotiations. It is suggested that excipient suppliers prepare in advance a quality agreement based on the template to be used to begin the negotiation process with their customers when a quality agreement is requested. As with any binding agreement, it is advisable to seek the review of legal counsel of all companies that are party to the agreement. QUALITY AGREEMENT RESPONSIBILITIES AND REVIEW Effective implementation of any quality agreement is dependent on both excipient supplier and user ensuring that the obligations of the agreement are consistent with the quality systems at the respective sites. Use of a template allows a supplier to conduct this review once, prior to initiating any quality agreements with users. Any obligations or commitments added during the negotiation phase of an agreement should require additional review of the affected quality systems to assure compliance prior to signature. When a supply agreement exists, or is being generated at the same time as the quality agreement, reviewers should assure that any quality provisions captured in the supply agreement are also reflected and/or not contradicted in the quality agreement. It is dependent upon both parties to assure the quality agreement is maintained as a current, accurate document during the entire effective period. Amendment(s) and/or addendum(s) may be needed to assure the current requirements and/or responsibilities are reflected in the quality agreement. Both parties are responsible for reviewing requests for amendments/addendums to assure the quality systems support such changes. All quality agreements and amendments/addendums require legally binding signatures. It is the responsibility of each party to assure the signatures in the quality agreement reflect the legally binding signatures representing each party. Manufacturers Quality Agreement Template Introduction/Purpose Scope Parties to the agreement Example wording: This Quality Agreement is by and between with office at
, hereafter referred to as and with office at
, hereafter referred to as . Whereas, supplies excipients suitable for pharmaceutical use to . Note: Company name can be expanded to include further descriptive information about the company such as Company X, a manufacturer of pharmaceutical excipients duly organized and existing under the laws of . Specify excipients covered by agreement Example wording: This agreement pertains to the following excipient(s) (or excipient processes/types/locations, etc), hereafter referred to as : . Definition of the quality criteria Example wording: Supplier will manufacture, test and release the in accordance with the following quality criteria: Examples of potential quality criteria: IPEC PQG GMP, current version (Primary Reference) Others as applicable: GMP as published in USP General Chapter <1078>, current version ISO-9001, current version WHO Guideline on GMP, current version United States FD&C Act Misbranding and Adulteration Provisions Documented HACCP Concept Other regional certification, as applicable Responsibilities for quality activities Example wording: This Quality Agreement will outline the responsibilities of and with regard to the quality activities described in the quality criteria listed above. Site(s) involved Note: Sites supplying should be mutually agreed upon. The Supplier sites involved can be specified here if needed (may refer to an appendix). If the sites involved are not listed in this agreement, it should be indicated where the agreed sites are specified. Use of third parties Example wording: If uses third parties to manufacture, package, label, test or release , such use is set forth . Changes in the use of third parties as set forth in this agreement will not be made without prior written notification to the . shall, however, retain all obligations under this Agreement whether or not a third party manufactures, packages, labels, inspects, tests, releases or handles . Note: If this information is considered confidential, specify how this information can be disclosed to the customer, for example under confidentiality agreement. Term of agreement Example wording: This Agreement shall become effective and binding upon the date of the final signature and shall remain in effect until 2 years after the last delivery of by to unless specifically requests an extension of the Agreement. Either party may terminate this Agreement by giving 6 months written notice to the other party. After such termination, and if so requested by , will negotiate with in good faith a subsequent Quality Agreement. Assignment Example wording: Neither party shall have the right to assign any or all of its rights or obligations under this agreement without the other partys prior written consent, which shall not unreasonably be withheld. The foregoing notwithstanding, prior written consent shall not be required in connection with a merger, consolidation, or a sale of all or substantially all of partys assets to a third party, except if such merger, consolidation or sale is with a competitor of the other party. Confidentiality (optional) Note: May define here according to s policy or refer to other documents pertaining to confidentiality, e.g. confidentiality agreement (also referred to as a confidential disclosure agreement). Other agreements Example wording: If a supply agreement is in place between and , and there are any inconsistencies between the supply agreement and the Quality Agreement, the supply agreement will take precedence over the Quality Agreement. Choice of Law Note: If a choice of law is not specified in a supply agreement, a choice of law should be agreed to between the parties and designated here. Compliance See attached QA Responsibility Table. Manufacturing, Packaging and Labeling See attached QA Responsibility Table. Documentation and Records See attached QA Responsibility Table. Storage and Distribution See attached QA Responsibility Table. Change Control See attached QA Responsibility Table. Non-Conformance See attached QA Responsibility Table. Auditing See attached QA Responsibility Table. Quality Contacts List the contact persons from each party that will be responsible for communications related to this agreement. This information can be provided in an attachment. Signatories References List of Attachments Quality Agreement Responsibility Table ResponsibilitiesSupplierCustomerNAComplianceConform to the Joint IPEC-PQG GMP Guide and/or other quality criteria defined in the scope of this agreement. The current versions of the defined quality criteria in effect at the time of this agreement are attached. (Attachment of quality criteria is optional.)XXMutually agree upon specifications for the Excipients which are the subject of this agreement. Specifications in place at the time of this agreement are attached. (Attachment of specifications is optional.)XXChanges to the agreed upon specifications must be mutually agreed upon and communicated in writing between the parties to this agreement, except for compendial changes which can be implemented without mutual agreement. Compendial changes must be implemented by the compendial implementation date.XXEnsure that the specifications for compendial excipients are in compliance with the current compendia.XXManufacture Excipients that conform to the mutually agreed upon specifications.XUpon request, disclose to the Customer recent regulatory agency inspections and findings pertaining to the Excipients.XNotify promptly if, in the course of a regulatory inspection, negative findings are made related to the quality of the Excipients supplied.XXShall have a quality agreement with third parties used for production, packaging, testing or processing the Excipients in any manner, which could be viewed during an audit.XManufacturing, Packaging and LabellingDocument that manufacturing and packaging process are fit for purpose. Demonstrate the commissioning of critical systems and equipment used in the manufacture and control of the Excipient. Demonstrate that cleaning procedures are appropriate and their effectiveness has been demonstrated.XSamples will be retained for a period of ____ years from __________________ (specify).XAgree upon special labelling requirements.XXDocumentation and RecordsCertificate of Analysis will be supplied with each batch.XCertificate of Analysis will be prepared either according to the current IPEC-Americas Certificate of Analysis Guide for Bulk Pharmaceutical Excipients or an agreed upon alternative that is defined in this agreement (an example COA may be attached).XAgree upon special Certificate of Analysis requirements.XXWhere applicable, electronic signatures used on the Certificates of Analysis must conform to the requirements of the IPEC-Americas Certificate of Analysis Guide for Bulk Pharmaceutical Excipients or an agreed upon alternative that is defined in this agreement.XRecords required by the agreed upon quality system will be maintained for a period of ____ years from __________________ (specify).XStorage and DistributionMaintain and supply upon request documentation that supports the recommended storage and transportation conditions plus re-evaluation or expiry dates. XEnsure that Excipients are stored and shipped in accordance with manufacturers recommended storage conditions.XXWhere applicable, agree upon requirements for reusable shipping containers.XXChange ControlChanges will be evaluated and communicated based upon agreed criteria and timelines. Refer to the IPEC-Americas Significant Change Guide or specified alternative that is defined in this agreement. X Non-ConformanceAll non-conformance should be investigated. Where applicable this includes the identification of the root cause, a risk analysis (including the risk to other lots and the impact to other test results) of the actions taken for correction of the problem, prevention of future occurrence and the formal conclusion by Suppliers Quality Assurance. If an investigation reveals that there is an impact to Excipients received by the Customer, Supplier shall inform Customer without unreasonable delay.XOut of Specification (OOS)Out-of-specification (OOS) test results should be investigated and documented according to a documented procedure. XDeviationsIf significant deviations from an established process are recorded, there should be evidence of suitable investigations and a review of the quality of the Excipients.XComplaintsHave a written procedure to investigate and document quality related complaints. A root cause analysis, actions taken for correction of the problem, prevention of future occurrence and the formal conclusion will be provided to the Customer within a reasonable time after receipt of the complaint.XComplaints made shall at least indicate the Suppliers batch number of the excipient and complaint subject. The complaint shall be communicated to the Supplier within a reasonable time after receipt of the excipient. Samples will be provided where appropriate and available.XThe parties shall cooperate in the exchange of information required to effectively conduct an investigation.XXRecallsIn the case of a recall of the Excipients, Supplier shall inform Customer without unreasonable delay of the planned recall. XHave a written recall procedure.XCustomer shall notify Supplier of any finished product recall which has been investigated or is under investigation and has potential to be related to the quality of the Excipients, as soon as possible.XThe parties shall cooperate in the exchange of information required to effectively conduct a recall or recall investigation.XXAuditingHave the right to audit Suppliers facilities, systems and documentation, as they relate to the manufacture of Excipients, at mutually agreed upon times.XAllow Customer to audit facilities, systems and documentation, as they relate to the manufacture of Excipients, at mutually agreed upon times.XIf required, a confidentiality agreement will be executed within a reasonable period of time prior to the audit.XXCustomer shall issue a confidential written audit report to the Supplier, which will include audit observations, within X days (mutually agreed upon timeline).XSupplier shall issue responses within X days (mutually agreed upon timeline) to all observations in writing to Customer Quality Assurance. Where the Supplier commits to a corrective action, a description and timeframe for completion will be included in the written response.XWhere applicable, agree upon requirements for auditing third parties used in association with excipients production, processing, warehousing, or testing.XX Distributors Quality Agreement Template Introduction/Purpose Scope Parties to the agreement Example wording: This Quality Agreement is by and between with office at
, hereafter referred to as and with office at
, hereafter referred to as . Whereas, supplies excipients suitable for pharmaceutical use to . Note: Company name can be expanded to include further descriptive information about the company such as Company X, a distributor of pharmaceutical excipients duly organized and existing under the laws of . Specify excipients covered by agreement Example wording: This agreement pertains to the following excipient(s) (or excipient processes/types/locations, etc), hereafter referred to as : . Definition of the quality criteria Example wording: Supplier will conduct all activities concerning the Excipients in accordance with the following quality criteria: Examples of potential quality criteria: IPEC Good Distribution Practices Guide for Pharmaceutical Excipients, current version (Primary Reference) Others as applicable: ISO-9001, current version WHO Guideline Good Trade and Distribution Practices for Pharmaceutical Starting Materials, current version NACD Code of Management Practice Cefic/  HYPERLINK "http://www.fecc.org" \t "_blank" FECC Safety and Quality Assessment Systems (SQAS) Distributor/European Single Assessment Document (ESAD II) Assessment (Section F and G) United States FD&C Act Misbranding and Adulteration Provisions Other regional certification, as applicable Responsibilities for quality activities Example wording: This Quality Agreement will outline the responsibilities of and with regard to the quality activities described in the quality criteria listed above. Site(s) involved Note: Sites supplying should be mutually agreed upon. The supplier sites involved can be specified here if needed (may refer to an appendix). If the sites involved are not listed in this agreement, it should be indicated where the agreed sites are specified. Manufacturer and Use of Other Third Parties Example wording: Agreed upon manufacturer, manufacturing site(s) and other third parties are disclosed in . Changes in the use of third parties as set forth in this agreement will not be made without prior written notification to the . Supplier shall, however, retain all obligations under this Agreement whether or not a third party manufactures, packages, labels, inspects, tests, releases or handles Excipients. Note: If this information is considered confidential, specify how this information can be disclosed to the customer, for example under confidentiality agreement. Term of agreement Example wording: This Agreement shall become effective and binding upon the date of the final signature and shall remain in effect until 2 years after the last delivery of by to unless specifically requests an extension of the Agreement. Either party may terminate this Agreement by giving 6 months written notice to the other party. After such termination, and if so requested by , will negotiate with in good faith a subsequent Quality Agreement. Assignment Example wording: Neither party shall have the right to assign any or all of its rights or obligations under this agreement without the other partys prior written consent, which shall not unreasonably be withheld. The foregoing notwithstanding, prior written consent shall not be required in connection with a merger, consolidation, or a sale of all or substantially all of partys assets to a third party, except if such merger, consolidation or sale is with a competitor of the other party. Confidentiality (optional) Note: May define here according to s policy or refer to other documents pertaining to confidentiality, e.g. confidentiality agreement (also referred to as a confidential disclosure agreement). Other agreements Example wording: If a supply agreement is in place between and , and there are any inconsistencies between the supply agreement and the Quality Agreement, the supply agreement will take precedence over the Quality Agreement. Choice of Law Note: If a choice of law is not specified in a supply agreement, a choice of law should be agreed to between the parties and designated here. Compliance See attached QA Responsibility Table Manufacturing, Packaging and Labeling See attached QA Responsibility Table Documentation and Records See attached QA Responsibility Table Storage and Distribution See attached QA Responsibility Table Change Control See attached QA Responsibility Table Non-Conformance See attached QA Responsibility Table Auditing See attached QA Responsibility Table Quality Contacts List the contact persons from each party that will be responsible for communications related to this agreement. This information can be provided in an attachment. Signatories References List of Attachments Quality Agreement Responsibility Table ResponsibilitiesSupplierCustomerNAComplianceConform to the IPEC Good Distribution Practices Guide for Pharmaceutical Excipients and/or other quality criteria defined in the scope of this agreement. The current versions of the defined quality criteria in effect at the time of this agreement are attached. (Attachment of quality criteria is optional.)XXSupplier will have a Quality Agreement(s) with the original manufacturer and/or any third parties used for production, packaging, testing or processing the Excipients in any manner that could be viewed during an audit of the Supplier.XMutually agreed upon specifications for the Excipients which are the subject of this agreement. Specifications in place at the time of this agreement are attached. (Attachment of specifications is optional.)XXChanges to the agreed upon specifications must be mutually agreed upon and communicated in writing between the parties to this agreement, except for compendial changes which can be implemented without mutual agreement. Compendial changes must be implemented by the compendial implementation date.XXEnsure that the specifications for compendial excipients are in compliance with the current compendia.XXSupply Excipients that conform to the mutually agreed upon specifications.XUpon request, disclose to the Customer recent regulatory agency inspections and findings pertaining to the Excipients.XNotify promptly if, in the course of a regulatory inspection, negative findings are made related to the quality of the Excipients supplied.XXProcessing, Packaging and LabellingWhere applicable, appropriately document all processes related to the Excipients such as processing and packaging are fit for purpose. Demonstrate the commissioning of critical systems and equipment used. Demonstrate that cleaning procedures are appropriate, and their effectiveness has been demonstrated..XIf Excipients are repackaged, processed or packaged from bulk, samples will be retained for a period of ____ years from __________________ (specify).XAgree upon special labelling requirements.XXDocumentation and RecordsCertificate of analysis will be supplied with each batch in accordance with the IPEC Good Distribution Practices Guide for Pharmaceutical Excipients or an agreed upon alternative that is defined in this agreement.XWhere applicable, the certificate of analysis will be prepared either according to the current IPEC-Americas Certificate of Analysis Guide for Bulk Pharmaceutical Excipients or an agreed upon alternative that is defined in this agreement (an example COA may be attached).XAgree upon special certificate of analysis requirements.XXWhere applicable, electronic signatures used on the Certificates of Analysis must conform to the requirements of the IPEC-Americas Certificate of Analysis Guide for Bulk Pharmaceutical Excipients or an agreed upon alternative that is defined in this agreement.XRecords required by the agreed upon quality system will be maintained for a period of ____ years from __________________ (specify).XStorage and DistributionMaintain and supply upon request documentation that supports the recommended storage and transportation conditions plus re-evaluation or expiry dates.XEnsure that Excipients are stored and shipped in accordance with manufacturers recommended storage conditions.XXWhere applicable, agree upon requirements for reusable shipping containers.XXChange ControlChanges will be evaluated and communicated based upon agreed criteria and timelines. Refer to the IPEC Americas Significant Change Guide or specified alternative that is defined in this agreement. X Non-ConformanceAll non-conformance should be investigated. Where applicable this includes the identification of the root cause, a risk analysis (including the risk to other lots and the impact to other test results) of the actions taken for correction of the problem, prevention of future occurrence and the formal conclusion by Suppliers Quality Assurance. If an investigation reveals that there is an impact to Excipients received by the Customer, Supplier shall inform Customer without unreasonable delay.XOut of Specification (OOS)Out-of-specification (OOS) test results should be investigated and documented according to a documented procedure.XDeviationsIf significant deviations from an established process are recorded, there should be evidence of suitable investigations and a review of the quality of the Excipients.XComplaintsHave a written procedure to investigate and document quality related complaints. A root cause analysis, actions taken for correction of the problem, prevention of future occurrence and the formal conclusion will be provided to the Customer within a reasonable time after receipt of the complaint.XComplaints made shall at least indicate the Suppliers batch number of the Excipients and complaint subject. The complaint shall be communicated to the Supplier within a reasonable time after receipt of the Excipients. Samples will be provided where appropriate and available.XThe parties shall cooperate in the exchange of information required to effectively conduct an investigation.XXRecallsIn the case of a recall of the Excipients, Supplier shall inform Customer without unreasonable delay of the planned recall. XHave a written recall procedure.XCustomer shall notify Supplier of any finished product recall which has been investigated or is under investigation and has potential to be related to the quality of the Excipients, as soon as possible.XThe parties shall cooperate in the exchange of information required to effectively conduct a recall or recall investigation.XXAuditingHave the right to audit Suppliers facilities, systems and documentation, as they relate to the handling of Excipients, at mutually agreed upon times.XAllow Customer to audit facilities, systems and documentation, as they relate to the manufacture of Excipients, at mutually agreed upon times.XAgree on requirements for auditing by the Customer the original manufacturer or other third parties.XXIf required, a confidentiality agreement will be executed within a reasonable period of time prior to the audit.XXCustomer shall issue a confidential written audit report to the Supplier, which will include audit observations, within X days (mutually agreed upon timeline).XSupplier shall issue responses within X days (mutually agreed upon timeline) to all observations in writing to Customer Quality Assurance. Where the Supplier commits to a corrective action, a description and timeframe for completion will be included in the written response.X GLOSSARY Active Pharmaceutical Ingredient (API)  Any substance or mixture of substances, intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or any function of the body of man or animals. Agreement Arrangement undertaken by and legally binding on parties. Batch (Lot) A specific quantity of material produced in a process or series of processes so that it can be expected to be homogeneous. In the case of continuous processes, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval. Batch Number (Lot Number) A unique combination of numbers, letters and/or symbols that identifies a batch and from which the production and distribution history can be determined. Certificate of analysis A document listing the test methods, specification and results of testing a representative sample from the batch to be delivered. Cefic The European Chemical Industry Council Commissioning The introduction of equipment for use in a controlled manner. Contract Business agreement for supply of goods or performance of work at a specified price. Corrective Action - A change implemented to address a weakness identified in a management system. Critical A process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the excipient meets its specification. Customer The organization receiving the excipient once it has left the control of the excipient manufacturer; includes brokers, agents and users. Deviation Departure from an approved instruction or established standard. Distributor All parties in the distribution/supply chain starting from the point at which an excipient is transferred outside the control of the original manufacturers material management system including parties involved in trade and distribution, (re)processors, (re)packagers, transport and warehousing companies, forwarding agents, brokers, traders, and suppliers other than the original manufacturer. Excipient Substances other than the API which have been appropriately evaluated for safety and are intentionally included in a drug delivery system.  HYPERLINK "http://www.fecc.org" \t "_blank" FECC European Federation of Chemical Distributors GDP Good Distribution Practice. GDP deals with the  HYPERLINK "http://en.wikipedia.org/wiki/Distribution_%28business%29" \o "Distribution (business)" distribution of products, including requirements for purchase, receiving, storage and export. GDP regulates the movement of products from the premises of the manufacturer to the end user, or to an intermediate point by means of various transport methods. GMP Good Manufacturing Practice. Requirements for the quality system under which drug products and their ingredients are manufactured. Current Good Manufacturing Practice (cGMP) is the applicable term in the United States. For the purposes of this guide, the terms GMP and cGMP are equivalent. IPEC International Pharmaceutical Excipients Council IPEC PQG International Pharmaceutical Excipients Council and the Pharmaceutical Quality Group. ISO International Organization for Standardization. Label The display of written, printed or graphic matter on the Immediate container of the excipient (inactive ingredient) product. Labeling All written, printed or graphic matter accompanying an excipient at any time while it is in-transit to the customer or being held for sale after shipment or delivery to the customer. Lot see Batch Lot Number See Batch Number NACD National Association of Chemical Distributors Manufacturer A party who performs the final processing step. Original Manufacturer Person or company manufacturing a material to the stage at which it is designated as a pharmaceutical starting material. Packaging The container and its components that hold the excipient for storage and transport to the customer. Procedure Written, authorized instruction for performing specified operations. Quality Agreements - Legally binding agreements that are mutually negotiated between users and suppliers. They are intended to be an agreement between quality departments. A quality agreement is intended to be a formalized, joint agreement on quality responsibilities and activities defining both the users and suppliers respective obligations as they relate to quality. They are intended to address quality commitments between the parties and are based on the quality procedures in place. Quality Assurance The sum total of the organized arrangements made with the object of ensuring all excipients are of the quality required for their intended use and that quality systems are maintained. Recalls A process for withdrawing or removing a pharmaceutical material from the distribution chain because of defects in the materials or complaints of a serious nature. The recall might be initiated by the manufacturer/importer/distributor or a responsible agency. Record Document stating results achieved and/or providing evidence of activities performed. The medium may be paper, magnetic, electronic or optical, photography etc. or a combination thereof. Retained Sample Representative sample of a batch/delivery that is sufficient quantity to perform at least 2 full quality control analyses and will be kept for a defined period of time. Site A location where the excipient in manufactured. This may be within the facility but in a different operational area or at a remote facility including a contract manufacturer. Specification The quality parameters to which the excipient, component or intermediate must conform and that serve as a basis for quality evaluation. Supply chain For the purpose of this guideline, supply chain is defined as all steps in the entire chain of distribution starting from the point at which an excipient is transferred outside the control of the original manufacturers material a management system downstream to the final user of the excipient. Supplier Person or company providing pharmaceutical starting materials on request. Suppliers may be distributors, manufacturers, traders, etc. User A party who utilizes an excipient in the manufacture of a drug product or another excipient. USP/NF United States Pharmacopeia/National Formulary Validation A documented program that provides a high degree of assurance that a specific process, method or system will consistently produce a result meeting predetermined acceptance criteria. WHO World Health Organization     Copyright 2009 The International Pharmaceutical Excipients Council Page  PAGE 4 of  NUMPAGES 25 Copyright 2009 The International Pharmaceutical Excipients Council The IPEC Quality Agreement Guide and Template 2009  5 > f g h ) * C D F G # & h ǹrgUrgQQh)(#j3uJ hiQhJECJUVaJhiQhJECJaJjhiQhJECJUaJhVUhJEh%]hYhJEh%] hVUhJE hYhJEhJE hVUhk.h(1W5OJQJ^JjhUmHnHujh+UmHnHu)jh{Z5OJQJU^JmHnHu)jhGD5OJQJU^JmHnHu > ? h ( ) G H gd#gd=gdY$a$gdJE & FgdJEgdJEgdYgd#)$$d%d&d'dNOPQa$gd#gdkKgdk.  01qrsthi,67@AWX_`o #$WXY}}}}v hk.h# hk.h y hk.hnr hk.hIUG hk.h hk.hbhk.h"/h(1WmHsH h"/h(1WOJQJ^JmHsHh"/hN}mHsH h"/h)( h"/h| h"/hN} hk.hN} hVUhN} hk.h(1WhJE htuhY. /Lk1Lqrt$a$gdL 7$8$H$gd(1W & Fgda & Fgdagdnjghhi{ ! !"""&&>(?((((++gdnjgdnjYZ^_lmu  /0z{EF4]^gh +45>?!CDiz h2h2 hk.hJ hk.h# hk.h5 hk.h( hk.h hk.hh hk.hb hk.hIUG hk.hnrGzPQXY    !!s!z!!!!!""ϺȳϺȳ h2hl/R h2h(1W h2h# h2h* h2hve h2hj# h2hr h2h)k h2h5 h2hh h2hjB h2h7 h2hnr h2hb>"""\"]"z"""""%%%:%;%&&''''''('(/((((((((())));)F)R)W)))!***2*9*>*L+M+T+U++++++*,3, ----|-}--------˽ h2h2 h2hK= h2h2 h2h h2hW` h2h#h2 h2h( h2hl/R h2h(1W h2hbH+--............/*0+011p^pgd"p^gd"p p@^gd"p^gd8p^gd"p & Fgd"p^gd] $^a$gdkKgdtugdnj------8.;.?.@.G.H...............//ӽviXJXvh]OJQJ^JmH sH  h$h@EOJQJ^JmH sH h8ph]OJQJ^Jh@EOJQJ^JmH sH #h$h]>*OJQJ^JmH sH  h$h]OJQJ^JmH sH +hkKh]5CJOJQJ^JaJmH sH +hkKh]5CJOJQJ^JaJmH sH h$h]mH sH h$hbOJQJ^J h2hhU h2h2 h2h// //t/u/}/~/////////00'0(0)0*0+011A1B1C1K1R1S1T11ᷦ}pf\hJtcOJQJ^Jh@EOJQJ^Jh$h@EOJQJ^Jh]OJQJ^Jh$h]OJQJ^J#h@Eh]6OJQJ^JmH sH  h$h@EOJQJ^JmH sH h]OJQJ^JmH sH h@EOJQJ^JmH sH h(OJQJ^JmH sH  h$h]OJQJ^JmH sH hJtcOJQJ^JmH sH  1B1C1T1112202222223R3l333344?4@4 8h^8`hgd"p  ^ `gd"p  ^ `gd8pp^pgd"p^gd"p11111111111222'2.2/20282`2b2k2l2222222222I3J3R333ŸŸٮŸŸn] h$h OJQJ^JmH sH  h$h]OJQJ^JmH sH h"pOJQJ^Jh8ph]5OJQJ^Jh8ph]OJQJ^JhOJQJ^JhJtcOJQJ^Jh$h@EOJQJ^Jh]OJQJ^Jh@EOJQJ^Jh$h]OJQJ^Jh{qjhdOJQJ^JhdhdOJQJ^J$333344>4?4@4H4O4P4Q4V4g44444444444455¸vvvvi\Ohih4U OJQJ^Jhih]OJQJ^Jh$h4U OJQJ^Jh4U OJQJ^Jh(OJQJ^JhJtcOJQJ^Jh$h@EOJQJ^Jh]OJQJ^Jh$h]OJQJ^Jh@EOJQJ^J h$h]OJQJ^JmH sH  h$h~_OJQJ^JmH sH h~_OJQJ^JmH sH h OJQJ^JmH sH @4Q44455"6#68696J6%8&888888:::: ;<<=^gd"p 8h^8`hgdip^pgd"p55&5(51525T5U5X5Y5556"6#68696A6H6I6J66668"8$8޽ޯ{q{gZPFZPZh/]OJQJ^Jh3OJQJ^Jh{qjhdOJQJ^JhOJQJ^Jh@EOJQJ^Jh$h]OJQJ^Jhih4U OJQJ^Jhih]OJQJ^Jh$h4U OJQJ^JhJtch]6OJQJ^Jh%6OJQJ^JmH sH #hJtch4U 6OJQJ^JmH sH #hJtch]6OJQJ^JmH sH hJtc6OJQJ^JmH sH $8%8&8,8888888888$9(9C9D999ò{m\K=h4U OJQJ^JmH sH  h$hdOJQJ^JmH sH  h{qjhdOJQJ^JmH sH hdOJQJ^JmH sH hPOJQJ^JmH sH h@EOJQJ^JmH sH hih4U OJQJ^Jh]OJQJ^JmH sH  h$h]OJQJ^JmH sH h$h4U OJQJ^Jh4U h]6OJQJ^Jh4U h4U 6OJQJ^Jh4U OJQJ^JhdOJQJ^J999999999999999:!:#:Z:_:`:p:q::::::::::::::::::::::; ; ;ӴӦӦyh@EOJQJ^JmH sH  h$h:OJQJ^JmH sH h/]OJQJ^JmH sH h]OJQJ^JmH sH h(OJQJ^JmH sH  h$h4U OJQJ^JmH sH  h$h]OJQJ^JmH sH h4U OJQJ^JmH sH h3OJQJ^JmH sH . ; ;;;<<<=== =)=*=2=4=g=}=~==================±±{{{i{i{i{i{i{±[h@EOJQJ^JmH sH #hhX6OJQJ^JmH sH #hh4U 6OJQJ^JmH sH #hh]6OJQJ^JmH sH #hh6OJQJ^JmH sH  h$h4U OJQJ^JmH sH h]OJQJ^JmH sH  h$hOJQJ^JmH sH  h$h]OJQJ^JmH sH hPOJQJ^JmH sH "=======>>>>y?z?????????@@ h@^gd"pgdkK & F h@gd"p h@gd"p^gd"pp^pgd"p^gdi====>> >!>)>*>/>0>8>:>i>j>p>q>>>>>>>>>>>>>>>>y?z??ᩘᩘtb#h$h]>*OJQJ^JmH sH #hh]6OJQJ^JmH sH #hh6OJQJ^JmH sH  h$hSWOJQJ^JmH sH h]OJQJ^JmH sH h(OJQJ^JmH sH h4U OJQJ^JmH sH hXOJQJ^JmH sH  h$h]OJQJ^JmH sH hOJQJ^JmH sH #???????????@@:@;@=@U@W@X@|@}@@@@@@@@@@@@@@@AAA0A1AABν}l h$hSWOJQJ^JmH sH #h8ph]>*OJQJ^JmH sH hkOJQJ^JmH sH hSWOJQJ^JmH sH #h$h]>*OJQJ^JmH sH  h$h]OJQJ^JmH sH hkOJQJ^Jh$h]OJQJ^Jh$hSWmH sH h]>*OJQJ^JmH sH )@<@=@W@X@~@@@@@@@@@@@@AA0A1AAAAAA & F h@gd"p h@gd"p h@^gd"pAABB,B-B>BGBPBSB $IfgdjYgdkK $^a$gd9 h@gdd & F h@gd"p h@gd"p BBB+B,B-BSBTBbBsBBCC"EpEEEEFWF_FFxk^QkDhch OJQJ^JhchOJQJ^JhchJOJQJ^JhchJ OJQJ^JhchAVOJQJ^JhchdOJQJ^Jhchd5OJQJ^Jh$hjYmH sH +h$hd5CJOJQJ^JaJmH sH +h$hjY5CJOJQJ^JaJmH sH +h9hjY5CJOJQJ^JaJmH sH #h$hd>*OJQJ^JmH sH SBTB_B`BaBbB^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcbBcBlCnCpCqC^UUUU $IfgdjYkdK $$Ifl\m,"?9 t0644 laytcqCrCBDDDFDGD^UUUU $IfgdjYkd $$Ifl\m,"?9 t0644 laytcGDHDqEsEuEvE^UUUU $IfgdjYkd $$Ifl\m,"?9 t0644 laytcvEwEEEEE^UUUU $IfgdjYkd $$Ifl\m,"?9 t0644 laytcEE4F6F7F8F^UUUU $IfgdjYkdG $$Ifl\m,"?9 t0644 laytc8F9FFFFF^UUUU $IfgdjYkd $$Ifl\m,"?9 t0644 laytcFFFFF,G7GAGBGCGDGGGGGGHH H$H%H-H2H@HNHUHiHlHHHHHHHH̲̿̿|o|obo|U|UU|hchInOJQJ^Jhch!%0OJQJ^JhchOJQJ^JhchEOJQJ^Jhch~ J5OJQJ^Jhchd5OJQJ^Jhch5oOJQJ^JhchHOJQJ^Jhch|5OJQJ^JhchAVOJQJ^JhchdOJQJ^JhchOJQJ^Jhch@ OJQJ^J!FFAGCGEGFG^UUUU $IfgdjYkd $$Ifl\m,"?9 t0644 laytcFGGGGGGG^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcGG H!H"H#H^UUUU $IfgdjYkdC$$Ifl\m,"?9 t0644 laytc#H$HEIGIHIII^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcHICIIIIIJJ/J0JDJEJJJ?K@KGKHKVKWKsKKK6LM M$MEMyMMMMMMپٱپٱ٣ٖٖٖى٣پ|ooehXOJQJ^JhchJ OJQJ^Jhch%OJQJ^Jhchy~_OJQJ^JhchrOJQJ^Jhchd6OJQJ^JhchyOJQJ^Jhchd5OJQJ^JhchJf$OJQJ^JhchdOJQJ^JhchInOJQJ^JhchEOJQJ^J"IIJIIIII^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcIIIIII^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcIIIIII^UUUU $IfgdjYkdM$$Ifl\m,"?9 t0644 laytcII0J2J3J4J^UUUU $IfgdjYkd $$Ifl\m,"?9 t0644 laytc4J5J/K1K2K3K^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytc3K4KmKoKqKrK^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcrKsKxLzL{L|L^UUUU $IfgdjYkdI$$Ifl\m,"?9 t0644 laytc|L}LMMMM^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcMM M!M"M#M^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytc#M$MMMMM^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcMMMMMMMMMMM7NJNNNNNOO O%OhOiOyO}OO̿}pbWJhchr/bOJQJ^Jh5 T5OJQJ^Jhchd6OJQJ^JhchZOJQJ^Jhch$J$OJQJ^Jhchd5OJQJ^Jhch`OJQJ^Jhch)OJQJ^Jhch?OJQJ^Jhch3OJQJ^Jhchd#XOJQJ^JhchJ OJQJ^JhchdOJQJ^Jhch]OJQJ^JMM1N3N5N6N^UUUU $IfgdjYkdE$$Ifl\m,"?9 t0644 laytc6N7NNNNN^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcNNNNNN^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcNNcOeOfOgO^UUUU $IfgdjYkd$$Ifl\m,"?9 t0644 laytcgOhOiOyOzO{O|O^YPPPP $IfgdjYgdjYkdA$$Ifl\m,"?9 t0644 laytc|O}OnQpQqQrQ[RIII $IfgdjY $Ifgdykd$$Ifl4\m,"?9 t0644 laf4ytcOOGPJPqPPPPPQQQmQnQoQsQQRR RR\R]RRRRRRiSSSS0T8TOTPTTTTTUUUU佰䰣{{{{n{{{{{{{{{hchZOJQJ^JhchdOJQJ^Jhchd5OJQJ^Jhchs:OJQJ^Jhch3OJQJ^Jhchd#XOJQJ^Jhch OJQJ^Jhch$J$OJQJ^Jhch9OJQJ^Jhchr/bOJQJ^Jhchr/b5OJQJ^J+rQsQQQQQ[RIII $IfgdjY $Ifgdykd$$Ifl4\m,"?9 t0644 laf4ytcQQRR R R[RIII $IfgdjY $Ifgdykd$$Ifl4\m,"?9 t0644 laf4ytc R RRRRR[RIII $IfgdjY $IfgdykdO$$Ifl4\m,"?9 t0644 laf4ytcRRRRRR[NEEE $IfgdjY & F$Ifgdckd$$Ifl4\m,"?9 t0644 laf4ytcRRRRRR[RIII $IfgdjY $Ifgdykd$$Ifl4\m,"?9 t0644 laf4ytcRRSTTT[RIII $IfgdjY $Ifgdykd $$Ifl4\m,"?9 t0644 laf4ytcTTUUUU[RIII $IfgdjY $Ifgdykdc!$$Ifl4\m,"?9 t0644 laf4ytcUUUUUU[RIII $IfgdjY $Ifgdykd("$$Ifl4\m,"?9 t0644 laf4ytcUUUUUU[RIII $IfgdjY $Ifgdykd"$$Ifl4\m,"?9 t0644 laf4ytcUUVVVV[RIII $IfgdjY $Ifgdykd#$$Ifl4\m,"?9 t0644 laf4ytcUUUUUEVVVWWWWWWWWWWXXDXJXSXXXXXXYYYY!Z@ZZZ [̻̭̿󓆓viihch97OJQJ^Jhch)u:h)u:OJQJ^JhchsFOJQJ^Jhch)u:OJQJ^JhchvNOJQJ^Jhchd5OJQJ^JhDhchd#XOJQJ^JhchDOJQJ^Jhch OJQJ^Jhchr/bOJQJ^JhchdOJQJ^J$VV@VBVCVDV[RIII $IfgdjY $Ifgdykdw$$$Ifl4\m,"?9 t0644 laf4ytcDVEVWWWW[MDDD $IfgdjY$Ifgdyo^:kd<%$$Ifl4\m,"?9 t0644 laf4ytcWWWWWW[MDDD $IfgdjY$Ifgdyo^:kd&$$Ifl4\m,"?9 t0644 laf4ytcWWWWWW[RIII $IfgdjY $Ifgdykd&$$Ifl4\m,"?9 t0644 laf4ytcWW?X@XBXCX[RIII $IfgdjY $Ifgdykd'$$Ifl4\m,"?9 t0644 laf4ytcCXDXXXXX[RIII $IfgdjY $IfgdykdP($$Ifl4\m,"?9 t0644 laf4ytcXXIYKYMYNY[RIII $IfgdjY $Ifgdykd)$$Ifl4\m,"?9 t0644 laf4ytcNYOYYYYY[RRII $IfgdjY $Ifgd*kd)$$Ifl4\m,"?9 t0644 laf4ytcYY[ [ [ [[RRII $IfgdjY $Ifgd*kd*$$Ifl4\m,"?9 t0644 laf4ytc [ [[[[[[RRII $IfgdjY $Ifgd*kdd+$$Ifl4\m,"?9 t0644 laf4ytc [ [k[l[[[[[[[[[[[[\\\\ \!\&\7\\\\\\\\\\\\\7]8]@]Ϲm_____________h\uHOJQJ^JmH sH #h$h\uH>*OJQJ^JmH sH  h$h\uHOJQJ^JmH sH +h$h\uH5CJOJQJ^JaJmH sH %hX5CJOJQJ^JaJmH sH +hkKh\uH5CJOJQJ^JaJmH sH h\uHOJQJ^JhchS2OJQJ^JhchOJQJ^Jhch?OJQJ^J%[[[[[[[[RF=5= & Fgd5 T^gd\uH $^a$gd\uH Ugdl/Rkd),$$Ifl4\m,"?9 t0644 laf4ytc[[[\\!\C]D]1^2^Z^[^l^__6_7_H___L`b`|`  ^ `gd\uH  ^ `gd8pp^pgd\uH^gd\uH p@^gd\uH^gd\uH@]A]B]C]D]]]1^2^Y^Z^c^j^k^l^^^^^^__5_6_?_F_G_P_V___8`K`L`b``ᳩ~l~[ htuh\uHOJQJ^JmH sH #h8ph\uH5OJQJ^JmH sH  h8ph\uHOJQJ^JmH sH h{qjh\uHOJQJ^Jh h\uHOJQJ^Jh\uHOJQJ^Jh$h\uHOJQJ^Jh\uH6OJQJ^JmH sH #h@Eh\uH6OJQJ^JmH sH  h$h\uHOJQJ^JmH sH h\uHOJQJ^JmH sH #````aa=a>aBaCaaaaaa2b3b4b[b\beblbmbnbsbbbbbbbbbbccc+cлллЪ{q{q{q{q{q{q{q{q{q{h\uHOJQJ^Jh$h\uHOJQJ^J h+nh\uHOJQJ^JmH sH  hkKh) OJQJ^JmH sH  hkKh\uHOJQJ^JmH sH )jhtuh\uHOJQJU^JmH sH  htuh\uHOJQJ^JmH sH  h$h\uHOJQJ^JmH sH h\uHOJQJ^JmH sH %|``aab3b4b\b]bnbcc-c.c@dAdmd~d9f:ff 8h^8`hgd8p 8h^8`hgd9  ^gd\uHp^pgd\uH 8h^8`hgd\uH^gd\uH  ^ `gd\uH+c,c-c.c4cEcOc$d@dAdRdYdfdmd|d}d~ddddef9f:fffffffgg3g8g9g=gųų}}}p}bh4U h\uH6OJQJ^Jh{qjh\uHOJQJ^Jh\uHOJQJ^J h$h\uHOJQJ^JmH sH h$h\uHOJQJ^JhJtch\uH6OJQJ^J#hJtch\uH6OJQJ^JmH sH h\uH6OJQJ^JmH sH h9h\uHOJQJ^Jh\uHOJQJ^JmH sH  h\uHh$OJQJ^JmH sH #ffffgiiii ijjkkkkkk lllllmm h@gd\uHgd\uH^gd\uH^gd\uHp^pgd\uH=gXggggggggggggggg.h6hohthhhhhhhhhhhhhhhhiii iiiii ijjkkkkkkll l lllll4l5l=l>lClDlLlNl}l~lް#hh\uH6OJQJ^JmH sH hXOJQJ^JmH sH h\uHOJQJ^JmH sH  h$h\uHOJQJ^JmH sH  h{qjh\uHOJQJ^JmH sH E~llllllllllllllllmmmmmm n%nKncnennnnnnn%o6oo p p1p2pｰ～ｈreh=h\uHOJQJ^J+h$h\uH5CJOJQJ^JaJmH sH +h9h\uH5CJOJQJ^JaJmH sH #hkKh\uH>*OJQJ^JmH sH h$h\uHOJQJ^J#h$h\uH>*OJQJ^JmH sH #hh\uH6OJQJ^JmH sH h\uHOJQJ^JmH sH  h$h\uHOJQJ^JmH sH 'mmmmm n n%nJnKnennnnnnnnnn$o%o6oooo h@gd\uH h@^gd\uH & F h@gd\uHoooop p1p2pCpLpUpXp $Ifgd\uHgd= $^a$gd9 & F h@gd\uH h@gd\uH 2pXpYpgpwppevvwwwwYw\wwwx/xxxyEyyyy9zc{{t|| } }}~y~~~~~ـڀ߀pqv1<r h.JRh\uHh_5OJQJ^JhXOJQJ^Jhch\uH6OJQJ^JhOJQJ^Jhch) OJQJ^J#hch\uH6OJQJ^JmH sH hch\uHOJQJ^Jhch\uH5OJQJ^J9XpYpdpepfpgp[RRRR $Ifgd\uHkd,$$Ifl\m,"?9 t0644 laytcgphpqqqq[RRRR $Ifgd\uHkd-$$Ifl\m,"?9 t0644 laytcqqrrrr[RRRR $Ifgd\uHkdv.$$Ifl\m,"?9 t0644 laytcrrdsfshsis[RRRR $Ifgd\uHkd:/$$Ifl\m,"?9 t0644 laytcisjstttt[RRRR $Ifgd\uHkd/$$Ifl\m,"?9 t0644 laytcttuuuu[RRRR $Ifgd\uHkd0$$Ifl\m,"?9 t0644 laytcuuRuTuUuVu[RRRR $Ifgd\uHkd1$$Ifl\m,"?9 t0644 laytcVuWuuuuu[RRRR $Ifgd\uHkdJ2$$Ifl\m,"?9 t0644 laytcuu_vavcvdv[RRRR $Ifgd\uHkd3$$Ifl\m,"?9 t0644 laytcdvevvvvv[RRRR $Ifgd\uHkd3$$Ifl\m,"?9 t0644 laytcvvwwww[RRRR $Ifgd\uHkd4$$Ifl\m,"?9 t0644 laytcww]x_x`xax[RRRR $Ifgd\uHkdZ5$$Ifl\m,"?9 t0644 laytcaxbxxxxx[RRRR $Ifgd\uHkd6$$Ifl\m,"?9 t0644 laytcxxxxxx[RRRR $Ifgd\uHkd6$$Ifl\m,"?9 t0644 laytcxxyyyy[RRRR $Ifgd\uHkd7$$Ifl\m,"?9 t0644 laytcyyzzzz[RRRR $Ifgd\uHkdj8$$Ifl\m,"?9 t0644 laytczzzzzz[RRRR $Ifgd\uHkd.9$$Ifl\m,"?9 t0644 laytczz{{{{[RRRR $Ifgd\uHkd9$$Ifl\m,"?9 t0644 laytc{{o|q|r|s|XOOOO $Ifgd\uHkd:$$Ifl4\m,"?9 t0644 laf4ytcs|t|||||[RRRR $Ifgd\uHkd;$$Ifl\m,"?9 t0644 laytc||(}*}+},}[RRRR $Ifgd\uHkdD<$$Ifl\m,"?9 t0644 laytc,}-}}}}}[RRRR $Ifgd\uHkd=$$Ifl\m,"?9 t0644 laytc}}}}}}[RRRR $Ifgd\uHkd=$$Ifl\m,"?9 t0644 laytc}}~~~~XOOOO $Ifgd\uHkd>$$Ifl4\m,"?9 t0644 laf4ytc~~~~~~XOOOO $Ifgd\uHkdZ?$$Ifl4\m,"?9 t0644 laf4ytc~~~~~~~XOOOOO $Ifgd\uHkd$@$$Ifl4\m,"?9 t0644 laf4ytc~~ڀ܀݀ހXOOOO $Ifgd\uHkd@$$Ifl4\m,"?9 t0644 laf4ytcހ߀XOFFF $Ifgd\uH $IfgdtkdA$$Ifl4\m,"?9 t0644 laf4ytcqstuXOFFF $Ifgd\uH $IfgdtkdB$$Ifl4\m,"?9 t0644 laf4ytcuvXOFFF $Ifgd\uH $IfgdtkdLC$$Ifl4\m,"?9 t0644 laf4ytc,./0XKBBB $Ifgd\uH & F$IfgdckdD$$Ifl4\m,"?9 t0644 laf4ytc01<=>?XOFFF $Ifgd\uH $IfgdtkdD$$Ifl4\m,"?9 t0644 laf4ytc?@jlmnXOFFF $Ifgd\uH $IfgdtkdE$$Ifl4\m,"?9 t0644 laf4ytcnoXOFFF $Ifgd\uH $IfgdtkdtF$$Ifl4\m,"?9 t0644 laf4ytcXOFFF $Ifgd\uH $IfgdSkd>G$$Ifl4\m,"?9 t0644 laf4ytc XOFFF $Ifgd\uH $IfgdSkdH$$Ifl4\m,"?9 t0644 laf4ytc XOFFF $Ifgd\uH $IfgdSkdH$$Ifl4\m,"?9 t0644 laf4ytcXOFFF $Ifgd\uH $IfgdSkdI$$Ifl4\m,"?9 t0644 laf4ytc}~XJAAA $Ifgd\uH$IfgdSo^:kdfJ$$Ifl4\m,"?9 t0644 laf4ytcXJAAA $Ifgd\uH$IfgdSo^:kd0K$$Ifl4\m,"?9 t0644 laf4ytcXOOOO $Ifgd\uHkdK$$Ifl4\m,"?9 t0644 laf4ytcXOOOO $Ifgd\uHkdL$$Ifl4\m,"?9 t0644 laf4ytcr{>?ŌЌ f5ď滱xxsmxbx[ h#hk hQ8hk h8{5 hPJ h5 h2hk h2hk PJ hQ85hQ8hk 5h2hk 5 hkKhk hS hk OJQJ^Jhk OJQJ^JhjYh\uHOJQJ^Jhch\uH>*OJQJ^Jhch\uHh)u:OJQJ^Jhch\uHOJQJ^Jhch|OJQJ^J=?@AXOOOO $Ifgd\uHkdM$$Ifl4\m,"?9 t0644 laf4ytcABXOOOO $Ifgd\uHkdXN$$Ifl4\m,"?9 t0644 laf4ytc "#XOOOO $Ifgd\uHkd"O$$Ifl4\m,"?9 t0644 laf4ytc#$ĉʼnljȉXOOOO $Ifgd\uHkdO$$Ifl4\m,"?9 t0644 laf4ytcȉɉ݊ߊXOFFF $Ifgd\uH $IfgdkKkdP$$Ifl4\m,"?9 t0644 laf4ytcŌ XSNINDDgd#gdkKgdk gd\uHkdQ$$Ifl4\m,"?9 t0644 laf4ytc f5őY?ה;Ֆ5̘R%CyKʞgd#5?(GőϑYd?Jהؔ 9:;@A]pqԕՕԖՖږ5ѱ~wwll~lwjh2hk U h#hk h2hk 0JB*phhQ8hk 0J5B*ph-h2hk 0JB*CJOJQJ^JaJph6jh2hk 0JB*CJOJQJU^JaJphh h2hk hQ8hk 5 h#hZhQ8hZ5 hQ8hZ0JmH nH sH tH *5=̘ҘR\CIКKVǛ"5RʞӞ؟X^tz٤eԥ٥LMSTUVZ[eƿhGDmHnHujhk.haU hk.hah,[jh,[U h2h]hhX h#hk hQ8hk 5 h2hk h#hk 5Cʞ؟Xt٤ԥGjk $7$8$H$a$gdk. $7$8$H$a$gdk  Ugdl/R h@gdk gd#efhijkŦƦզ֦צĻukd`Y h2h]hl˾ w Ax]KGm,2Ql!a GH >,@H8 @B(V$b%@b[qb;<6NJǞ=cγ臘ҟ[3̼7]ߺW}=s~rUmwQU[VTU_q~x_-oi|a ?aZs2{2sAAAAAAAAAAA.]8މsjთ6xͥ^rux-gR|\glCȉxyڻ{[u_w{8c+jI:e^3sh59? SkY^GO7LpȟXk!o6|L;~Ώ:nV슾cqO~`u '4m{&/c󣎛1tjra '?ȃ6lBa9Ƨ C|#_ߥN??.w;3?$j_}eƖNJŏX8ZWCf\ ?t͑))W}-7f~;D&8|y5 M=D&v~?A~x9lWnZ3w3 soud]}]_C|f*}B8ԑiwWǏ#+Y_|?3b1=1 x|6O PAAAAAAAAAAAAAADN B $dfkBubo=qo?~;:I(rod٣ՍOɅ9y{^YgOn_g7^ ^س|3;c x.>@/@^ެ>|i~̧Ď'Nwpru]޼{Z}uCB2~^omdM :=s.[gWKl)%Sv@\y+byOoEgϤB>aTX$&qH c+얮_Z֨m~f0TKK{*l;g ŌcF>3My-G~4 tʁ=?,zFPN9s@u_7?fS駠&읷~CSw /N~S{ #ϓ'@킙k}=L~W >xW$f,*ج%cq|'=O,غ"?v׹G+`J#?ǧ+O^̪ߏrTvky@,ܴJ%? r2ׯ,?Cۊ?'/yƕkS%ĭȏa!7Oϣu_~뛀7ܟ.2hރ3DV7.:9U ~he羮@ܡ g<`5F35ڒ1ì=r/Ë)b*f]?){ʏg#|mB}kV vu%e!~@̜PlnQ9vj,Rr;e_m_Nc9rP ~,C83HXzj{L;67~ؽ$~ԇvŦG9!ZNO_̥5.D\vN|0CekZW'Q|Vw`MM9rBZKM݌o\ſ3r~ɻh/>? BTKkF'j Ȟ뺏bb`җ>lGbysV4{hmuStKY]Ýx1 `=7:Vm8KxfkFWϗʑ{}n9ÅxBlcQG곃#rm5'L6>6p͛Y!2V~hcM i}f #!෯N~3Jӥ!Gs9́}Niiȁ.U/h9X?vD;Kp9K6I~E;A~LϥnǐsdžUhScj8\;FmN>bژs1.c`W]z]Ɂ.q7㭭ݐ}xZhzhm`ޭ{7c1Skց|Sͻ5h=*Zߨ k(uTtfi{r}6_[NrZ;u\ץoGrv^&VSԝݺ5*`=r靓>㮘f6V<u 8ӓE^?). 9ȍfaS+]+.Yg }oM޶.v2(Hs{=8Cm}TC֗.X5S>}+Gd~_3s۱r}?#TcsHBe/o17sގP2~]ᙤۆ1^L]s.=~}זj LB\}b\X;Ƭ]۾Ϡ1jlU X(clzgCVwޤS`dn>0X38և+r&9)7y6u'Rˌ4D1Ըq|}[H޽o[ }8a?xy2]: ;e.=~չX٣HctA˼j *r^Θ*6ռ 6l/蔡s~4['ǮBy":|7L4z nq{Bh, cKKs _SPgOƔ񟊿Q?+|A^з_+u5n7J;ۿJ^/3iBP>Cӆ#vK.z{-9Apr$gEha#i4zy99`1FEMȾ c /Z '&ҧg]&}l׵:j_^}ԩS馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n馛n6_0Y0/冋z]y}py0:p bf2ּhNǰÑz,OEOpl\Nz~?N.z>6χaWMǯF)^o~_{Pu ^¹WÎ'|[`1znB)W86}MpǗ7kt/Dč|L{;: ۧnZbO\ZvnMl6/ǯO3P3'DŠ&Lɏzɏ:lf <ؙ?SUw0]crZ`u{Q(O%7'G .9󕥈%y>fǫI炏_?Y{G{ǙO&$l6֢">}/g [f'o|ͫ"nƏP]YYAgC :l-rCEOn9:u60#6?IO/m:X2G3O_rE8%m3" ZE[:S~9f-xmVƸ@%|_T Yݰ9bjG{yď 1b1S_FmfUt}[>‚sTARx 3Kqߞuo & n_|fv$5ŭR { n&_8$x)^eC臭/?#Yh?qxu o 3j !j썄g%N{5#-tonxvKr|ߙSLy+LYt?.[:mYONTytλ]?xotJ>ӫcr7auAcMf&&A_l4%lƁE\v yPpt uGX4<}<.7ůD7~edy (+ƾb  rܞp"~¹nwcҒyﰚΑ݊*nc0kQd=:K5}ny=K^z"__ 0uנr3݊kEk>?epe4l&WŭŖI. rИKxxM#;6Ic q 'S5^K}cOpګ2?q<[2C0UE*ΐNK?B$gqF}^sYέYM俴4_H8D /<Soq~c񃖆:S>P|Nˠ##r@8N೧*;?e gR[UORr%ƣ5^c'i-6˹szLjLxE`$ .C^+iM o,7ɧ]v*iW5R8 %~٥6?=O=1XL8{W4|}*WO >Ě%>CzR/-}Y['s֡ALCPｪ7,_>ڣHy`-G]r, ^Z"sҜ_J>mW{$-o}OgSI~Ոw_CCj,^n_ߟy:Y΂p|=/?%Nyut/A7LpKnV>(boBKP[ƩzY[6ʽz^bo{NܟDGW{{a#NuxIg\cA=FCIS\.rǜ`?9_7-%l ֤2^pSgw{㿙s]^O}hNM"3W@wH>c\$LM:?g0fw/Eu\}n|[>jPA{(t!YO1b?Hg[-x]' u,oxOž >F^-&\_;5_s;)GEMCݝto%f"zOΑ<6B_؝ ϽU k2a`c2瑿 qg tzIc.8)vVs75Y3ǶRqx{Xf,pͩb'ԊUbN ;{4.uHNOߜ/)yJ]u=ܞp?^b a,y9In?OV9B]U5i 'Nu~nԵ9rm)}HY$9Mf{Gb(iODKO S#wK si~< 7ъͫyPMK. g>B )Iʍ( :Kp}X22 H/ANC{o Z/F´o!㙇p(m*w|W 9v Lj|%xħ2/<2Boe.|!z=ӮA@ jYgfZtgeq:jŕ\-y)N2A_GT C_/xŞ='g^ڜ# ńGa6tNh>//zF_yܗ! 08_$ =*`CZG<\k1Ud9K f—QI4f0d@Ѫe)9v ;XYL}Za=O}'r%\_TbE8 5<]?5^Ά 4e%~[/To904X4|U\xn> 3 Y6[r{ ;-57>/u؉ fmh*ΒS?бZ<~r*j;ˑL~]+3y[ȽUu݆cfU *oXI]ɯϷr"|;TTn>:MNMzQQ*A-}Gfm|C?O83K"ʱvz p= 4 m ;ddz.ai|.7'>g9a1KQ2.Bsb?qɷ` p;]Zu5=܏{(=Ǽ&v fNQ*b/XP6j7{ Oja[+6V!f(LC |*CEpGɨV9tpB<eˆ'ᶛap)@@p9sz;GTMmec.>Մ߼'[Les4/x57Qs6;=ϥ*gD@u;4:ϖ[v4/3P CuF+wZGxWi[34Rp{_pWŀ꥔|$ j.~;xZo*B %Xž;$z'Šo`= cXB=P6׵|tsC3 '`\ͷejqgHM8UizpzS]Q\qXSśl|Vת2K|c3RLjCs8ZWἇeCm>V ?OʫTĜ\Rutg벫__k:}suPdχ?\ ZJ{04n">\=*gɑ:c~Tjs!z^0Ө3&Z1UyVz 1*V̊CSMs8yS{/@KN[¾< _sܾ ޶UeJ _Rr2OܻPH;cʏx8֬J?능A..p\>Mkȥ'c1^V}{v"^S++9eY%ޟr{S9~r胵0ԧaa;h*VϦ+u}Wjn[;:by0xe;ko7&>M>y,_I;^zUwVTKy{<5]WƬT srTΡdl ZcaOբ%%,-[Q-~{SSCrڥ?Di. DW"<}#^{pEX>Y ϡvrKgSqgВ!ţCWe!KPYJ" 1cJM_@ןO5ON陪p}8ֈ `הN=KH3{ġ/Y` ]#;3~iUq/*}e&(W4$sr9Q.:E2g6 vPe~]뗾J$HS_A0Q:-xBOm6V>o ?ߦ;GS?DU'3{Y&'KUC2?Z_=^[?/|v^_4ѫ.}_9LfшOX_g|TS D+-eaKw 1U˳)D?b+{_PqI{Y'TSnb'݄w& }mǤ7_Σ|k{Ow v0O΃a!mAUDMW_Èr+<$dƽo<κto\)%Efؽ$J^{8 m}f$A(] |E4$;?;d9* 7`h{gCq_+v8F5'Of_& ,KN9sUI}݀lpH-d? LwXiw16@;Jbc'P ~+s+2' lX9}TĕD0 }7&-KEi@~CF7 p{>D9N_q+6xCGzۈxCXcOE8B߮vj"lC؟gE ڮ9nض!슉`{gx;:{t!)(}omMdVŸ0(+|a@FJ{bW>JgQvr=GQ{brFo}yymxxaPڭ+|o"rQ٬/7{*r 9~zgU6@jrD޲VGSnnYbfjWןWGvpBf57{̚q4X`䯊y/DMh.{?QvkEͶ).wWb4 F˅nAы"|k(fnh3q/yEnס8Oi}*&ߌww_BÚ~Ω~ l%>' bוɳr 3sU&qlΉa{ f`Ǣ#f(=VC]dg?)^myM7+.} JSg]3+[(Έ}h JV-AY46MT.}qI+)z.ogsI*7a!Jxy:o@k:f=Ӊ9}<ʊT =a īKi­p 0&~br Kùq}HgMxj ?cGj} ( := V-{e j^FWvgx~4}AMއ+ڥ<2:#Ż>d.weGKyyM>縵B|?qv;}k:_`[H bL_4|߫ZYFG+Dp3Я/%OƎ.PQ+O?6=}gX3;F/9݉%wZtKbǧ!fװum.Yoml߮ÎBڢ=q {ğg48}uںd; x r-S^˹Q֓-+WZ*kxO{j/K1kye hs|a3-E9^Mc&4x5\ϼH2se/d bFmN<ëդD pΏԠWiHKFSQDVOP L+GjSaہ:_.%Յksġ^Ҩe{**[B!wv4x*3Y?`~:(> x#p0^a9OFGuM8 \MʵPC7vjZjRk\kRW}05~ah &5pER4uŰoS}:V.4cDM{:]*p&ϦC=SBЯB8()'1k٣-:Is!^ FyVcKYRd}*g>Bj;k;9Wz%簃8AB"q|@ck=Z ,wanE3$'}%pX:K\_B{WyBڨgM;!z|_ӻ0v5EEz9o50ԥa>Kψy`DnʣK2ka^f:|h~[[r`iXvy΁>4%e#\f@rwrDX[~xeݭ!vpZu&'ȎsOq/t~dw8/ztK Ps92{=Q4Kqް+As eo}_v}|,gR ː#}O-@Sw"ot>9>NC.Ypd>s읕]g}XP*c6 هp,f;9?0ߏM0v̔_ȫ%k*͞`mgu֭;vj۷=:'ܛ/kM⇕vʃ߳q͢wv^`q|m7Sj3<$Ni}3 َr}C(^ hF #s<)>獛0y? Sw\bKd֒rI? zy^"_1h.Ŭǁx4*D8|`/ښqyK﹣;|" vYOu~N}v ~{okڕ, ^7_^s6@‰^oYS|yu=땥y/C'Msu>|gO}al7cDz{t}lҖGS$?v'r^yR~GjB> ػ}ۼ{ּgD,F;_]vqGK-;e9kL寸Gͭ94 IOM|.% 9OEFt8 ,Og_b~r9[?nhq6g0Ã`;]}j-'3!oێ8jײCaC+}}nm߱];3pӒ/>)v~c^KŽ%ޱ8ˤ!|$_ S w;9r|Z7Ih.s1Z=#50t^w_WwN؇dn߭.io{tėm<Jt隁GƷߏaߧiZ?!=5y$]__~';lp9̦{̟FEI=c)E6Yñ{ZPxIs~I~G]DM yw q*Ҝ]^Wqj h;SP-sņ0E ͹ /{ң^h Gsjt8oogmqj;?%̿yvۤv%Tg~d| Q}W?%COJZzt\ 2 jaVJs;v C ѵ~2Uk'vef]SƿU|ap)f9tdh2(}s'iSиg0~ 0軈=z=0Ȧ} e_Ϥ;n'9,$ij?ן' b\2r5]%-?8oGɖ 7a7ط 4*֮s ]Rd|V3=vYdhYZ<{x>Κ[giy3u1ԛ9 5ǃ%ǬIB+0?D6:2!#΁rm>̕"v"w6>KO3|ՈcuYO[-;nj#N6;2[d_'Fآ}QdApLI7;ZD˂ ՞iށs7V5$n3%/KPI$N#>/g+p*ݐٿX6eƄkm#\ٷ#,4(;;.}X2BGsDAxmOƞtمcuO@β1v|ǁxx]k7J^yzhr>ѝ[ͧz>Wz)vLZv/vǽ]zE!z~~]0FX&xX9 Kqr֩㿛5"B5σ~4|op@v8]%$}enTd%OݕerGr0U#e䭥al:t>lܡxΣxNR@˛hM朣f }F;sgDCG#{n[zni>iGZ`K,ŕ GAX[s4\hl;‘ q4|sP\*|iVd|WgXIi=R6&åG~At?}LTn:kk3qݍuZoD=pO{\.GCUn&m6=COq>,.7lxWe=זa#Ӱuohˤ}R,1?x6-[_e].e)!~U6E}{҂ ߪȧ1VO-ٙL'`:X;[`hpϧaKWU;1}J\fnb%wc#f/XS4妟ޛ<*[qoPf.ό/?J漟lt]++ZϬ+|J3<YJͱ 5@Gv$iqf쟢4=̽\^aͩ_\3ڡ,\n3 ;6k2uزM0@cB>A;oGS; w}{׬grs`jk75 uEu_X#cGwjyrݑwW Lɐ.5y ;&} .|y_W.^J?-pޚt3{j^Ln<;s WFܸ'aۑLl/Br>A.:ъVc¿.3>sw ɼ0֏%|[alRxQϘooGCmАt| ~xZJxN/;9Rb[׵i(ۆ;y9w51r~ G1q|.` ~{W#N]vq8#)̐<޸$%?t_ǮLmހ͛il6·'Ĝig*ሾg/"H{c| i-C[ h)ނ>79k:NC/ U~鏷ח8XN8.^"y%fАI>7#Gcv[ָ1xs-?tvӮt/6$ʏ1^8ZRNieHφ[tD {?{?zӵ!\[哝G>Or.X_#+y)fm~L~=J|>Ka[j78`L70+_ԾemYA=k5JH~FvLeK~ؐ*5ξtt1 .S?nȾYmpu2Ok7ؾX3~7`#%h~:ї|ϐ_anGE#S1H'=V54:fq܄kj.;(.ۥ^sc}ʩhZyG7߃4v1DuO'18-koRwM+ZɷIZsc=@7l~y_ӂ_'Zt{>oֲ.E ]6Ao7JIX34'لF<T9PsUHuz[|sU[~J،}p,p;*JQȤjʝ^su' bJ}aTuZI)n]׬W0w%wg R}߅!zrlV+$bt[EkiR Ҵ)t2N J}g|n~Uw 1iDԯ-6'Q&]N2-D IŻlv/[8Wbیf`$4;E+˞+t}?j]$u|m8X[4_Ĭ^}<ޣMho!#թ3|VH =π[\#;BiFwM֤*툺{ 'tzPR|>΋] hq2;.dg!;~9kdG=% J7d_SW\cofæ{J.%i/x e;ŞsqmNm"[ {pI9Yj Ώ=PGxfP'`>0aсzUw'+sa#E۾nSCҳcˤ[}ݱOY$Irvgsl@eZ V g?NFUX;9`Ǝh)y;Rfy9VK{m>݇FtLΚHmwZ_`WXODGXFshz>9D"vL ?qE{܏!1y9#Q]j;W>jSbۂ?`#3g/]Dž(-*d?0z-%k2G$ -Z=+> ns/'kO8G]mͅYt Đ.2 GokPWd^{h>.ǍJ侼 -25P!]I;$|Z~l8oq3ע:9.vP5Fzε0S"q!cpiX5v&:w˾IFcN,@ٳ{QMv:ϔZIY;&2f}T_x+|N1{U>g<=q`/b|;5NI|X\)vh&ٗP?y{^=tΑGڏAGe,ZOa p~M[QƈX9ܰ&CZRwɺ2kY3I]D[؃c{ˤ̃uf 'yGt(BMW[\ {T]=@/LWcwcݿɫd4Jn%tJcH>(ޏk.>8'Ow fC}gٷдK -{5<\x[sQ K`:Y~E!s!q~JLJێeyjE hH ؝vوS-]iDbe%Dįj_~ A-n# 9>4:#탭Oh:b'+a^WCkW"g1?V;Jw5JypDɯo(-`mJD/o<:#zfN-[g|EđJۊhL\z5㲣eWe~:}6w);J/Ul:+]PG;2-gy$,FŇoo譯Y~_8nrڝN3st]ayuX=fOzܗv8gvKxflzxm1aWf1yh҇3Y0 RZO!Bۭ"sB\3β΄񢧹9;`YPe#gX㖉 هAip}:̸G1w]Z7d>8R; v,vEgYrA21Yp)ԎcõN}2꠪'j@a¼BżYUqa:<ㆆBypZrL;5cY1Χ[je=lf=6 ߍԧ.7K Q!Ko57+ t<]mhLKB&yh9q|}w;TwE|S='lvDw.Tc0PTЉf}ػm~^57paESNN밚M6$e۱aT'#{}ZnrZ=J,Ź?҂_Cܜbh,:)c3p􀪱_\LjwN4u>'`=N kqɗ=tڥi䧉&OoD_m+y~ IsVޝOѣs{uXcuNN ӾZ~}ܨɀǵZ1_!3&Eыlad!/.0o4tۭZI?c[ࡷ"}ٟ c΃9C/gzh:^X ۍΪĽ l*0;L\&K$_o:Y+;Bfj׀8 <73 ;_X֫Bk5u@ HI:O zdu_K7Flqc^_>8R iEˍ|L.z[jP&#_>u3ew8P“PR߄g*iEc}܃0Ѧ8zؗ\39~'|o7]OSS<#as{ּLVdP,M5,PM;=Oroa% CĹ֖#]zT$jwTv yrt2y67A-\ l-F{/)v4<~9]iq ?6탱3a appp? PdK]&gja8\?joptqE+կ2Џ=c_88VU#<Ǒ:F~ˉ$g׿h0;~uu"yh?mTڣD S:9)߸1cFsP] 0Y$PV,@wx[HWtԹ> DCۉަRL~R}psp*?ɜe?g8:OwC ,G`6l臋<3{FMqn@̬#oNg5G]Vɵ7I'gvƒ1%*Cy ϹE NV~6kC/{URywb:^+|B ;~m,~*3ǺܳRUV_!7kHR  o9mKkF[+eSy; (z}\ӊo{:**Hۭ&[MyqiMmOs3Ftsi1HyXUyBBs!]k?˹BTt=)ײf>]̵5+ZvC<]m9*/#p/0?bmI_]'vdΌk6LCG}9LeZ b[fJ7.r 5O@u}.IKS59eހFSf<wD8fer mɕ0&U_vF#t!t*Wdck'8r:uƗ܎!6&+ h.o>#uˌRv"dlP3D;k O̥XƉز/r.R[&y@ݥƷq^cMNµB=v`QVo#3egĎb[q S[ۋ$bK^$}UE@||)~ *O|}aKD/^SM gwm|}隕|du]}(fW<~m.SUƭC#s3N;) ͢"yKސ5ƈ7[] Z! XṂn|a?4 ֈ k'b쑙i~6"·L<f/=>O/B3ڔ {+őV`q:.=?? 4DjVEܔo{X,:duڰcn΀_^Bo[y>'o2glF^;B:#l(}PZ^Hf (~4۬8e)^q +Ux_%:!vUHt D+קv3@_j k=~k0NyxsRDoESJc&㈙5l{ ŇGH8KV<!8?Op괟+}3~POW_X.Qs w܄4!b؉cИSaO4Z1_tgerγ߉I_}06#;o>^Eٚ=N[ˆUjM5(xa) eSyn֧n:藝Nm?~T9Ogr:%xʞ^P3X:ڰ۰a fF[dG9?Aڢ?BcO>%)Z_}^]༿gRn~ȋ{n'u[mH]pԝw%n1|#P ZAk~*}Iu:By3w6T}}vCgJͭܿtalmž/agl=ي~kgܫkZ$W+7k]涅<3&h=(>u+JH'徬KߊW9V5ž_}V.OVsOt!yC_dDcSY@핞}H9>ʹW4爛p+#o+( 2tU!-~叠My8QWC/.αDž'\BKijcpj/'z7P+BL\vNYL^Z.8Fi@+040z~A?~P󱲓m@qgݚ7;.fT|i#9,z߀5co e ?|UQuҭ}BsChM gxu[Pt&U=ăٿ;?y*\q1T [ǽk_ D_ɷ:C]S)qоNPh )J*KY7><[gL_R9c{:GuHS9H|3}2g=}0ZҿBH}$Ml&dDg{`6-VW3}uo#.ZhlCT|d=XŴ=:G< (I¤L9K%~֐jn_ABr*ucޤP9[}Mk)|lk7qTv*0>g>;Oqyl׼+7*L y/ nF,68gT9?g1)>ROk3H}dvGwdׯiGZi}G>٦Z4z:=+ohkU}.ݧDẽ;]UGuk雒8kazbiv3s@M0BCARN]yAm.!rp3;^7tM7tM7tM7tM7tM7tM7tM7tM7tM7tM7tM7tM/] jT͚Dd ^;<b  c $A? ?3"`?"ˁݻ_`e*)D$@=ˁݻ_`e*)\˽E2xxYklTE>w]ۖelBBˣ<{PX –N/^03PHZO Wo4阍pqUs'!1 PvBkܩVk]Gg'Ժҝ;t"*vXc6݃6݃vG~x\-lkj=O<~~f;sc7m`(NYkuNML#;lkMj.dZi/]O#cDKw{v鷯l0sE\vWn _̃Y .!â~px@OW@'F,`K`Z=l7WVܐp_3נz¥E>7{b#9ۻ>5U)S+g?1&Z:R9[:+As!ZE%Ƀx' L L,yȤĀ(+P@)0rZ:+vt/ԈcϾ?i6qP|^PR%au? g[~ל7\ĩQC&UMP`ʷTxuz ؇:eK~Gf]n p;"4cWr1[G>KQUTMx1"Q딻QTW~'7!\z/w#k@푎FT ⁂kޥ.0J1ӷ5XlƢ#^zrq yc=ۃ[ђ>g<}!|kssjoH\_N:\?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !^&6[*+,-./012345\89:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ]_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry F0x,( Data JRWordDocument &2ObjectPool`֜,0x,_1252685107F`֜,`֜,Ole EPRINT)CompObjs  !"#$%&'()+ FMicrosoft Visio DrawingVisio 11.0 ShapesVisio.Drawing.119q Oh+'0 X`lx  iain.moorel&=4*  EMFx@F, EMF+@``FEMF+0@?@ @ @Z@XLhB5Cw;C5CC!"CBw;C)BhB)B].BBhB5C@!b $$=='%  % V8'Q  # fuf %  % $$AAF`TEMF+@@4 ף>@$$==_888% % V8&P  # fuf % % $$AA( FEMF+*@$BBhB)B@0$G>ARIAL6@ Suppliers=g>u+>g>>g>v>g>>g>@?g>@?g>@/?g>J@?g>??   RpArial@|pOwhT4``w|xhm|OwPwKXJl&2|!&&D |8|2|||HC6 `wn\nq_&Nw>Pw\ndv% T>jm۶Am۶A>| L`Suppliers  % FxEMF++@ @XLK%DC,2CC,2C CRņCChCK%DChC?1CRņCK%DC,2C@$$==%  % V8-3C ''C  C '%  % $$AAF`TEMF+@@4 ף>@$$==_888% % V8.4C ''C  C '% % $$AA( FEMF+*@$BBK%DChC@0$*>ARIAL6@ Regulatory $=>D$>>>> >>>>x>>v?>Q?>@ 5?>AC?>X?>??   ( RpArialArial @|pOwh2||p|m|Z|m| @\ 0w|4HCh&|p|m|-w@\ !|-w 0w dv% T m۶Am۶A  LdRegulatory   % FEMF++@ *@$BBK%DChC6@ AuthoritiesJ=?Z$>?>?X>?>?C>?V ????@??')??@????   % T m۶Am۶A LdAuthorities   % FxEMF++@ @XLowC5CyC5C_oCByC)BowC)BCBowC5C@$$==%  % V8>Q ` f`f %  % $$AAF`TEMF+@@4 ף>@$$==_888% % V8<P ` f`f % % $$AA( FEMF+*@$BBowC)B@0$G>ARIAL6@h\UsersA>g>>g>>g>?g>?g>??   ( RpArialArial Arial2||p|m|Z|m| @\ 0w|HCh&|p|m|-w@\ !|-w 0w dv% Tlcjm۶Am۶Ac|LXUsers % FEMF++@ @C(CCQB3ACy+yB8LoCw+yB?Cl+yBAaCQBBaC%CBaC&CBaC&CBaC'CBaCl?CACn7eC=LoCn7eC3ACn7eCCm?CC)C@$$==%  ;U\  ; -;- - - - - TT T  <>>C % $$AAF`TEMF+@@4 ף>@$$==_888% % U\=D  ; -;- - - - - TT T  % % $$AA( FEMF+*@$BBCv+yB6@\PIPEC}$?m?Q2?m?S?m?t?m???   % Tdm۶Am۶ALTIPEC % FEMF++@ Ld&=3&=)??" FEMF+@ ObjInfo VisioDocument7"GVisioInformation" SummaryInformation( Visio (TM) Drawing "GOEyRxT|Om|| yOkY6Λ7 !fffMMM333Fwͩ}|kݝHxUJ:DT5I[1hXT@. /UbW##_b0zGz? L\&B1r&b%U& !oM $d ) P?;H$,Q, & #&J , 5& ?D#//?M?\.? CA  ~,,,'q/%P6$Y6 (}k?l)?"U   U%A3# o >S@#B:_a_ReUUeUeUeUeUeUePONODN`_ReUUeUeUeUeUUeUeUU/b SR%;5OM%>Qiq;RRRRgg Rqh>Qj /A^F' %p3:|bFpT#| | | vi?=Os<34x,,,/RQmeY q]U@QvovL__q____OO_OOTYA`,X@L&/d2?ɖQ3YҨsUΡ̦xΟ@$"Jʼ& ͥ*@d2A??ϟJ[D! f:45ŧ5ŷ5@ 0 0D$#    Q#b ; Chߠ Y ,00JDNrq(NN㊮NN(NN&&uc7D)KXXFNvvK&KD#KD#-D#NHGDB$KzzDKq%iz4 }1T\,Eu9fdhT,W'0΢Uܮ5E0 fI$[OmOC%ߑE##HZߪ  E,3Y&4JY&5&6<s9FaBaj+h8 8?&!3"DE=T;ܯ?w?@??8&t,'5UR^LY  Y7akKt//BJhuizpsĝa.1DTcAcpvOpM KKuhdX(G:iX IT[EEh.D#E,ah-50zG#zpvb aHGmc/QP K{\Hp_ hd? pA?%?7?I?[;<t5j! OO*FQ///F/K]SEn%cO@OOlE$g\Ey[EO_!_3_E_W_i_{_____VB506,HM.`e^MIa,>PbQaƒ2q? a%oXIoQfdoooSEX_O-OF6EDpE66Oҟm2Hg;pbӏ_ ,X7R[,Tful3~O贁Nk?JTf/6S?]?0'^5x@E@E@@t$ 'n/jRFfuOOo{o_0&G9O_KZk=_O_((]|Tq?Q);/q/ q58?Wf9|s???:etb< djb wOo"oOOO_/aoso; o-W,'HhWWCo/?I=)1DˠI 2DVOO_&Xoo+oooo9}-P|)CeɍU=O2b@b~qbYk}_ſ׿ˏ);M_qσϕϧ%7v [mur+b{r 0BTfx 0BTfxv9r7 }5GYk}Uc &8J\n/"/y!?"I/[/m/{.bLbݠ////// ??0?B?T?f?y???????? OO-O?OQOcOuOOx??OO,O>OPObOtOO_bksOOOOO_ _2_D_V_h_z__a=8\0ٶ_a=b;bbh_U./_oor-b@b3bDbMo _oqooojmizoooobݏ١&8J\nT2-?ȀIbQY1AByq1<֏ 0BTfxjPşן 1CUgyT W3!)9ت]2\nȿڿ]ߧCUgyϋϯ -?QߵuU45 ߤ߶ߊJ@J 1CUgy'9K]oTGFw?3{bq#]#.@)h('}o@o HZl~/ /2/D/T$1a/r8/)6Hx///&n|/??$?6?H?~???2$DPT<?qd@1m[Y/E1 $/T 6D UUF~@x!kbs{kbsFFzkF AJB PObBu B? "  U^pksVk`YdlĆ{ppjp_WODrag onut heqp ad mdi+f/ct/T rc sW],su5h%s]e:n&Wsw/tco wil/ztw Puue.H D  # =h8>TB ]]9 3gAUF~? ?F\.?PR6  iu`l?CuN Wbovv vLA aWB MJP,M&%JbrC `WJ`DA/^l)27#5 D@񣔑7#145 `?Copy igTtk(c])k2003kuM0c os0If21r01a0i0n.k WAl@ 8sBUe0e v@d0w/`V0s_SF.0hm!#C521w~7 ,CUFKJ9M3 7?T:p +bxvv &J?LᠡhML@l>]Uhz 1a2N0 RaXCJg7$M&d2?FB9R%6$R# Q$c  bM>8IZY'rA n2Naru567*?T"/UJe+C`h V*ca2#fE@{P~d0H:7$h6oi32_\ouRc`!>8 e 0s7iQeTj_HJBkHɏq(bUe_p PSO4 2A}` l2*MoL^i}(A5J7,j %oE*u5B*m w =_Hu+y׾ Ǵ"olJ3FOe#PB R%atW@o@OoP+UCA@BSdIp'UFDfP h>$/T 6D UUF~@xT E=R3AUF~?M&d2QR6  *uu`l?CuN b} ʆ` A"  >$ &"""P"J"yUI K@_bBo#/P6 *DJW`6!J`D=?^@ld&2H" o'{*L@"o#145 `?CopyrigTtk(c)k205@3kM!@c.@os@f'BAr@TAa'@i@n.k Alo@ HssBeG@eJ@v@dg@}/`V!@s__SFBg@cTm!#55B24|cK9M3 7?{* !7C1);5@D&?x( l>(>UhU5 A2s  a#Jn$& %23?TEF Pb3'* M(Ĩ*/(&&(k9oU*l3b $}Z&1`b2ncIrf5#pohorA rso ~6a1{qWg__Y%Np@2AyYMV-?lc5bY%in珔r5Ύ% T 8e bhe4'GSTA!iMJkb9l h5=I#C %p&CBpB`AA}b 5B/Xe.P L;g*@5Qcšţ(ZTl&@|RH'+# 8'~^VAuFlO\#S !B R]a@'"V@L/C#4aOW'U !"#t4*@@ % @ dK'}C-@/7"A!#'t4*@@ % @ Lz'}A-̉@7"AB@LO1'IR@O'IRH<(H<(BEO)( RE,O6( R(vdOSldK"B!O~&/?O'RPD]Cdg" cX,@H$?D"?w "*^p? N(tl*APA) TCU`2,cX,@H$D"? LFDNTyB@ uh$TB UF*@F@ % @FxP\#Ԕ (a}$?;afAt_Sup(lpEe0s@Oa8\~?"?mdTE#%Ҧ}&}&cW;ap1EUo2p9Ee (̭T?*JRm2fE`&]quOo  Ef`A/c@ L* F`/i޹f߹A _T oo)o;o_oqoofp8@@`0 eooooo"4Xj|y2U 1zgyH cu_@ϟ6R0g&l\@3yJd0A&tZ@1i0/5g29Xj8̯ޯ4?&8J\nȿڿ"?hOXj|?ϲ 0Tl_x߫____Q)$U8J\n_߮"@@>@~*+?ZkQTfqcr{eyp0;zյumZq(ߟ񘆱a,טM_ݿWm~C0w$c6~a~ձK]o Wᢨ< uM?J%$ѥ,߸b߻؍f1///>&?8?Cm?fETungaH"@&>fGSendya{ (  R$fERavi"&5<fGDhenu|"{a (  R$fELath#&<fEGautmi &<fGCordia New{ (  R$fGMS Farsi{{ ( _ R$fGulim"{a (  R$fETimes NwRoanz@D$JS3EBTJS74.BISe4%BdIS45BHS49BtHS4=BGS55CBGSx59B GS57BFS5=BFS%68BES]6'B,ES6"BDS6#BB@S+88B|@Sc8GBGuideTheDocPage-1"Gestur Fom aPrepaationViso 90Flow NrmaVi}so 0Co}nectrViso 01Viso 02Viso 03Viso 10Vi}so 1Viso 12Viso 13Viso 20Viso 21Vi}so 2Viso 23Viso 50Viso 51Viso 52Viso 53Viso 70Viso 80Flow MarkeFlow GrayCostDurationResour cRow_1AntiScalevisVerion Prepaation.2 Prepaation.4(On-pag_e rfnnc*))3L~:E3L:G3L:G3,hK:%G3$*S:G3|@:A3D*S;G3d*S;G3*S8;G3*SQ;G3*Sk;G3*S;G3+S;G3$+S;G3D+S;G3d+S;G3+S<G3+S<G3+S3<G3+SL<G3,Se<G3$,S~<G3D,S<G3d,S<G3,S<G3,S<G3,S<G3,S=!G3-S5=G3@Q=A3,LU=E3$-Sc=G3D-S}=G3DL=E3d-S=G3-S=G3ThK=$G3\@>A3hK>$G3H,>)G3ԉ@U>A  !"#$%&'(UbU U UUUt4*@@ %C @ CBNC-kBUQ7 A%t4 $kB_B A-4@7AJ@a[BOR@aB6RH<(H<(JEaD REda'D RUPT/\LbE C{  w"4FX,2,h(mg3@(y=7ȴ@ثz cK@PuB_OT }P OxS`L#<LU }CeB_o@ O(dR$|OR!)+'$O2h1SN3kҮlS8mP Y> T?  B*'"DS4P J#a/.,5oE6 iain.mooreMicrosoft Visio@ƺ՜.+,D՜.+,p, `ht  Croda Page-1d PreparationOn-page referenceN PagesMasters(DocumentSummaryInformation8 1TableSummaryInformation(DocumentSummaryInformation8 `ht_PID_LINKBASE_VPID_ALTERNATENAMESAOh+'0  0 < H T`hpxQuality Agreement TemplateasmithNormalUser8Microsoft Office Word@m@@xytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l t065?5595ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc$$If!vh5?5595#v?#v#v9#v:V l4 t065?5595f4ytc @gc՜.+,D՜.+,H hp  Colorcon LimitedP Quality Agreement TemplateQuality Agreement Template TitleTitel@4H`l _PID_HLINKSIAM_LGL_ENTITYIAM_SECURITY_CLASS IAM_REC_TYPEIAM_REC_MGT_DATEAl~ 9http://en.wikipedia.org/wiki/Distribution_%28business%29$^]http://www.fecc.org/$^]http://www.fecc.org/$ Dow CorningNon-Classified 05DEC2008  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH F`F Normal$a$CJ_HaJmH sH tH X@X  Heading 1$$x7$8$@&H$a$5mH sH tH J@J  Heading 2 $x@&5\]^JaJDA`D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List jj d Table Grid7:V0B'B dComment ReferenceCJaJH@H d Comment TextCJaJmH sH tH H"H d Balloon TextCJOJQJ^JaJLjL hComment Subject5\mH sH tH 4B4 uHeader  !4 R4 uFooter  !FVaF XFollowedHyperlink >*B* phPOqP \uHcefb021)7>*CJOJQJS*Y(^JaJo(ph<U@< \uH Hyperlink7>*S*Y(phVV k ceft031/57>*CJOJQJS*Y(\^JaJo(phRJR k.Subtitle5$7$8$9DH$5>*aJmH sH tH << nj Standard1$a$OJQJPOP #Heading 1 Char5CJ_HaJmH sH tH PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] @A@AD iG;y uu Yz"-/135$89 ;=?BFHMOU [@]`+c=g~l2pr5eTVYZ[]^`acdefhilty +1@4=@ASBbBqCGDvEE8FFFGG#HIIIII4J3KrK|LM#MM6NNNgO|OrQQ RRRRTUUUVDVWWWCXXNYY [[[|`fmoXpgpqristuVuudvvwaxxxyzz{s||,}}}~~~ހu0?n A#ȉ ʞkUWX\_bgjkmnopqrsuvwxz{|}~)CEY=YBY׌9pԍ:XXXV]_dor!  /X"$xD.^>l˾ w"$7 Vu Jl*oV@H 0(  (    6d1#"  `? V  3 #" `?bB   c $D "?V  3 #" `?\  3 A 3"`?\  3 A 3"`?B S  ? -(-ts%-(/tt0*-T2(lxl޾$]޾d]޾]޾d]޾]޾$]޾]޾d]޾]޾]޾$]޾d]޾]޾| ޾ ޾ ޾< ޾| ޾ II++YY%     KK++YY( B*urn:schemas-microsoft-com:office:smarttagscountry-region8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsplace ً $*[iq{ ,Y YRZfl')())Z22!6)6pAuADDGGTBUVVo`a5d=doo=tBtvvf;\Վ5ː ֞ٞ333333333333333333333333Lti{&'+++,z777778=8X88888889199c:>;r;<H<q=w===4>9>>>A?G??$@k@k@@@@@CACAAAAA0B5B/C4CmCsCxD}DE$EEEEE1F7FFFcGhGiG}GnIIJJJJKLMMMMNN@NENOOOO@PDPPPIQOQQQS SSSS!TVVYY``e6gghhoiijj8kjklllmmRmWmmm_nnoooo[o[ooooo$p%p/p/p@pEp]pbpppqqrrrrssott u u(u-uuuuvvvvvxxqyy,z@zj{o{L||| }}}}}~~~~rrzz=B$ŁɁ݂ццFGRS\]ՎAAOOQRԝGLVZŞƞk@k@@@@@CACAEESSVVYY``lloooo[o[ooooo$p%p/p/p u uvvrrzzццFGRS\]AAOOQR5d|\~VGY0[;q VGGj VGD02ࣈz1!VG>Z3!VGo!#VG=q)VG@t=VGABVG\iyPVG$RVG"UHX~'YB`VGi>dںLfVG^gVGclnVGspjT-+}VGp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHh ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.p^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp&^`B*CJOJQJaJo(phhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHh ^`hH.h ^`o(hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`hH.h ^`o(hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.p^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHh ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.p^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHp^`CJOJQJhHp^`OJQJ^Jo(hHop^`OJQJo(hHppp^p`OJQJo(hHp@ @ ^@ `OJQJ^Jo(hHop^`OJQJo(hHp^`OJQJo(hHp^`OJQJ^Jo(hHop^`OJQJo(hH"Usp5>Z3!'YD02i>do!#=q)AB\~-+}\iyPGj fz1!^g;q @t=$RB`clnY0HX :L                                   +b)9 4U J ) 1 8pY.hU(_@EJE}k  3!#$J$Jf$%)(@-r-k."/Q/!%0I,2`3e45z67:s:)u:K=tp?<@^BGDE*#S2AVk-*|5dt%Z(9Zd]} Q8G>%kKSW$LX_%097ve=nj yCjB#*3rVUZh?av#,,[`d  cR2>iJjr| sFLfNf#bBMZ jY~_|/HJ3yN}Rm|@ W`5Xy$O*P]] PSXt;IHhj#v@8@UnknownasmithG*Ax Times New Roman5Symbol3. *Cx ArialG5  jMS Mincho-3 fg5. *[`)Tahoma?= *Cx Courier New;WingdingsA BCambria Math"1hFJFJF.cPcP4d 2qXZ ]2!xxQuality Agreement TemplateasmithUserl                   CompObj*y